Association of SF-36 With Coronary Artery Disease Risk Factors and Mortality: A PreCIS Study

Preventive Cardiology

Volumn 13, Issue 3, 2010, Pages 122-129

  Zhang, Jian Ping ^a   Pozuelo, Leo ^a   Brennan, Danielle ^a   Hoar, Brian ^a   Hoogwerf, Byron ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ANAMNESIS; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METABOLIC SYNDROME X; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SHORT FORM 36; SMOKING; STATISTICAL SIGNIFICANCE; SURVIVAL;

ADAPTATION, PSYCHOLOGICAL; ALGORITHMS; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MENTAL HEALTH; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; STATISTICS, NONPARAMETRIC; STRESS, PSYCHOLOGICAL; UNITED STATES;

EID: 77955137057     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2009.00061.x     Document Type: Article

References (32)

1. McEwen BS. Seminars in medicine of the Beth Israel Deaconess Medical Center: protective and damaging effects of stress mediators. N Engl J Med. 1998, 338:171-179.
2. Miller TQ, Smith TW, Turner CW. A meta-analytic review of research on hostility and physical health. Psychol Bull 1996, 119:322-348.
3. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999, 99(16):2192-2217.
4. Vitaliano Scanlan JM, Zhang J. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med. 2002, 64(3):418-435.
5. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993, 270(15):1819-1825.
6. Blumenthal JA, Sherwood A, Babyak MA. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005, 293(13):1626-1634.
7. Taylor CB, Youngblood ME, Catellier D. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005, 62(7):792-798.
8. Wulsin LR, Evans JC, Vasan RS. Depressive symptoms, coronary heart disease, and overall mortality in the Framingham Heart Study. Psychosom Med. 2005, 67(5):697-702.
9. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide 1993, Boston, MA, The Health Institute, New England Medical Center
10. Barry LC, Kasl SV, Lichtman J. Social support and change in health-related quality of life 6 months after coronary artery bypass grafting. J Psychosom Res. 2006, 60(2):185-193.
11. Corcoran WE, Durham CF. Quality of life as an outcome-based evaluation of coronary artery bypass graft critical paths using the SF-36. Qual Manag Health Care. 2000, 8(2):72-81.
12. Bayliss EA, Bayliss MS, Ware JE, Steiner JF. Predicting declines in physical function in persons with multiple chronic medical conditions: what we can learn from the medical problem list. Health Qual Life Outcomes. 2004, 2:47.
13. Alonso J, Ferrer M, Gandek B. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004, 13(2):283-298.
14. Kosinski M, Kujawski SC, Martin R. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care. 2002, 8(3):231-240.
15. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285(19):2486-2497.
16. Konstam V, Salem D, Pouleur H. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am J Cardiol. 1996, 78(8):890-895.
17. Rodriguez-Artalejo F, Guallar-Castillon P, Pascual CR. Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure. Arch Intern Med. 2005, 165(11):1274-1279.
18. Konstam V, Salem D, Pouleur H. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol. 1996, 78(8):890-895.
19. Jiang W, Babyak MA, Rozanski A. Depression and increased myocardial ischemic activity in patients with ischemic heart disease. Am Heart J. 2003, 146(1):55-61.
20. Ruo B, Rumsfeld JS, Hlatky MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA. 2003, 290(2):215-221.
21. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med. 2003, 65(2):201-210.
22. Tapp RJ, Dunstan DW, Phillips P. Association between impaired glucose metabolism and quality of life: results from the Australian diabetes obesity and lifestyle study. Diabetes Res Clin Pract. 2006, 74(2):154-161.
23. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, 112(17):2735-2752.
24. Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24(4):683-689.
25. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003, 52(5):1210-1214.
26. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl. 2003, (134):10-17.
27. Oliveira GH. Novel serologic markers of cardiovascular risk. Curr Atheroscler Rep 2005, 7(2):148-154.
28. Rackley CE. New clinical markers predictive of cardiovascular disease: the role of inflammatory mediators. Cardiol Rev. 2004, 12(3):151-157.
29. Kaplan RC, Frishman WH. Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis. 2001, 3(5):326-332.
30. Collaboration FS. Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2004, 11(1):9-17.
31. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep. 2006, 8(5):421-428.
32. Yeh ET. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol. 2005, 28(9):408-412.